Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis.
about
Properties and use of botulinum toxin and other microbial neurotoxins in medicineBotulinum Toxin as a Pain Killer: Players and Actions in AntinociceptionMechanism of action of tetanus and botulinum neurotoxinsNeurotransmitter release is blocked intracellularly by botulinum neurotoxin, and this requires uptake of both toxin polypeptides by a process mediated by the larger chainTetanus and botulinum neurotoxins: mechanism of action and therapeutic uses.The cosmetic uses of Botulinum toxin type A.A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A).Botulinum neurotoxin and other treatments for fissure-in-ano and pelvic floor disorders.Drug Insight: biological effects of botulinum toxin A in the lower urinary tract.Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulismExpression of botulinum toxin binding sites in Xenopus oocytesExploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A.Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type ADevelopment of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype BBotulinum toxin type A for the treatment of migraine.The structure and mode of action of different botulinum toxins.Using translational medicine to understand clinical differences between botulinum toxin formulations.Use of botulinum toxins in cancer therapy.Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype ABotulinum toxin A for the treatment of chronic anal fissure.Botulinum toxin for the treatment of bruxism.Botulinum toxin for the treatment of bruxism.Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.Structure and function of Clostridium botulinum toxins.Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nervesCharacterization of the inhibitory action of botulinum neurotoxin type A on the release of several transmitters from rat cerebrocortical synaptosomes.Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A.Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E.Two Feet on the Membrane: Uptake of Clostridial Neurotoxins.Botulinum toxin-induced focal paresis in mice is unaffected by muscle activity.Microtubule-dissociating drugs and A23187 reveal differences in the inhibition of synaptosomal transmitter release by botulinum neurotoxins types A and B.Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes.Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.Botulinum Toxin for Central Neuropathic Pain.High resolution labeling of cholinergic nerve terminals using a specific fully active biotinylated botulinum neurotoxin type ADiscovery of a fluorene class of compounds as inhibitors of botulinum neurotoxin serotype E by virtual screening
P2860
Q23833526-B5133122-2338-414D-A5E8-63AFC410A5EEQ28084583-9F6A1EAD-1D0C-4A54-A042-9A64ED776B7CQ28609200-D091E435-3C0B-456A-92AD-5641DFCAF30CQ33579458-2052EEE4-752C-43FA-A4C9-FFDE55B31BF8Q33598965-A3839D6E-D64D-4B63-A5FB-1211DB98A5F1Q33750159-51ADFE67-0E6D-4ED8-BEFF-9269F1E187DCQ34675649-50D82495-0E73-4A02-A4EB-D0C2633D91CCQ34733600-37D33EAF-12BF-4C0B-80C0-666EE2B64D46Q34769979-0E7F28BA-8BF4-490F-9895-196A2599B0A3Q35057523-279DA21B-61C7-44DB-88E3-946CD019D85AQ35371760-98CB75E1-DDD6-4EDD-AD14-0CB64376B4D8Q35549101-9C6AE8DE-5B2F-4582-BC8C-37F1C2A6E0F8Q35697217-6AD2C8C5-1AC2-4C5F-AB5D-85984384F1B6Q35754894-645803BD-D271-44FD-B63A-BF335E4F5B43Q35779652-D411C256-0E2C-4BBF-A00A-785B8FE0A92CQ36488226-8229779A-C106-4724-B142-0B085F509403Q36656462-F3B6B17E-2C69-4B17-87DB-212788262DE3Q36656464-870E8E90-0151-4D30-8FF6-5F830CCC987EQ36715757-62A88D83-AF94-491D-880D-EB653168D8EEQ37274652-00164129-9BF8-48BC-A8DF-305B5680A841Q37345981-2F3B1152-4A86-4A3D-8FEA-A84B52A7D73DQ38239528-025C46C0-7898-48FB-9FF6-AF18C3B8F225Q38682484-4C051A3F-6CA4-4558-B499-5F734825825FQ39207459-733BD3C5-9721-44A8-9FC0-3B5695D2DFBEQ39264721-531977A5-672D-4D36-B770-5F36807B5B2DQ40439911-05FAAFAA-74B9-4CAB-A7F8-1C26313ACCE7Q41486002-7684712F-448C-473B-83FB-B0B1A361F870Q42202473-163E5E19-F382-4A58-A7BC-7E4F5B897F12Q45196654-EB0A74ED-8A4B-49B4-99B2-AAA9C43BD037Q45364853-77EB1A9A-6A4A-474F-8A9A-17BAB047927DQ48026258-A9CBBA7F-152B-4339-B7C2-54C43E51091EQ50790952-CBE61602-9CEE-42F5-A707-350B5597C96CQ52481316-1A00F602-BE60-4292-9CB8-265FB11D8FFEQ53877254-5FF8BFB8-25B6-4401-995F-F3041006238DQ55039946-4C107BD2-4D2D-4B47-ACFB-CF0B030137E4Q55498097-FD8F75A8-1F94-4610-BABB-13EE09579515Q58493576-EC7B2BFC-8B53-4E1F-B46E-1BE963CCAB34Q58824072-0142CAB4-163D-4465-9AA9-EBA6941C800B
P2860
Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Interaction of 125I-labeled bo ...... acceptor-mediated endocytosis.
@en
type
label
Interaction of 125I-labeled bo ...... acceptor-mediated endocytosis.
@en
prefLabel
Interaction of 125I-labeled bo ...... acceptor-mediated endocytosis.
@en
P2860
P356
P1476
Interaction of 125I-labeled bo ...... acceptor-mediated endocytosis.
@en
P2093
P2860
P304
P356
10.1083/JCB.103.2.535
P407
P577
1986-08-01T00:00:00Z